348 related articles for article (PubMed ID: 17377643)
1. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
[TBL] [Abstract][Full Text] [Related]
2. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.
Ohtani T; Hiroi A; Sakurane M; Furukawa F
Br J Dermatol; 2003 May; 148(5):1035-9. PubMed ID: 12786839
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.
Wadelius M; Stjernberg E; Wiholm BE; Rane A
Pharmacogenetics; 2000 Feb; 10(1):35-41. PubMed ID: 10739170
[TBL] [Abstract][Full Text] [Related]
4. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
Kumagai S; Komada F; Kita T; Morinobu A; Ozaki S; Ishida H; Sano H; Matsubara T; Okumura K
Pharm Res; 2004 Feb; 21(2):324-9. PubMed ID: 15032315
[TBL] [Abstract][Full Text] [Related]
5. Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.
Hou ZD; Xiao ZY; Gong Y; Zhang YP; Zeng QY
BMC Pharmacol Toxicol; 2014 Nov; 15():64. PubMed ID: 25413361
[TBL] [Abstract][Full Text] [Related]
6. N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.
Tanigawara Y; Kita T; Aoyama N; Gobara M; Komada F; Sakai T; Kasuga M; Hatanaka H; Sakaeda T; Okumura K
Biol Pharm Bull; 2002 Aug; 25(8):1058-62. PubMed ID: 12186410
[TBL] [Abstract][Full Text] [Related]
7. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men.
Hamasaki T; Inatomi H; Katoh T; Aono H; Ikuyama T; Muratani T; Matsumoto T
Int J Urol; 2003 Mar; 10(3):167-73. PubMed ID: 12622714
[TBL] [Abstract][Full Text] [Related]
8. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
Hirvonen A; Saarikoski ST; Linnainmaa K; Koskinen K; Husgafvel-Pursiainen K; Mattson K; Vainio H
J Natl Cancer Inst; 1996 Dec; 88(24):1853-6. PubMed ID: 8961976
[TBL] [Abstract][Full Text] [Related]
9. Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population.
Kiyohara C; Washio M; Horiuchi T; Tada Y; Asami T; Ide S; Takahashi H; Kobashi G;
Lupus; 2009 Jun; 18(7):630-8. PubMed ID: 19433464
[TBL] [Abstract][Full Text] [Related]
10. Significance of the genetic polymorphism of CYP2D6 and NAT2 in patients with inflammatory bowel diseases.
Dudarewicz M; Rychlik-Sych M; Barańska M; Wojtczak A; Trzciński R; Dziki A; Skrętkowicz J
Pharmacol Rep; 2014 Aug; 66(4):686-90. PubMed ID: 24948072
[TBL] [Abstract][Full Text] [Related]
11. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis.
Yee J; Kim SM; Han JM; Lee N; Yoon HY; Gwak HS
Sci Rep; 2020 Feb; 10(1):3658. PubMed ID: 32107440
[TBL] [Abstract][Full Text] [Related]
12. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
Suvichapanich S; Fukunaga K; Zahroh H; Mushiroda T; Mahasirimongkol S; Toyo-Oka L; Chaikledkaew U; Jittikoon J; Yuliwulandari R; Yanai H; Wattanapokayakit S; Tokunaga K
Pharmacogenet Genomics; 2018 Jul; 28(7):167-176. PubMed ID: 29781872
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis.
Woolhouse NM; Qureshi MM; Bastaki SM; Patel M; Abdulrazzaq Y; Bayoumi RA
Pharmacogenetics; 1997 Feb; 7(1):73-82. PubMed ID: 9110365
[TBL] [Abstract][Full Text] [Related]
14. Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes.
Doll MA; Zang Y; Moeller T; Hein DW
J Pharmacol Exp Ther; 2010 Aug; 334(2):540-4. PubMed ID: 20430842
[TBL] [Abstract][Full Text] [Related]
15. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
16. The role of N-acetyltransferase 2 polymorphism in the etiopathogenesis of inflammatory bowel disease.
Baranska M; Trzcinski R; Dziki A; Rychlik-Sych M; Dudarewicz M; Skretkowicz J
Dig Dis Sci; 2011 Jul; 56(7):2073-80. PubMed ID: 21321790
[TBL] [Abstract][Full Text] [Related]
17. [The associations of polymorphism of N-acetyltransferase 2 gene is associated with antituberculosis drug-induced hepatotoxicity in tuberculosis patients].
An HR; Wu XQ; Wang ZY; Liang Y; Zhang JX
Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jan; 45(1):36-40. PubMed ID: 21418817
[TBL] [Abstract][Full Text] [Related]
18. Differences in β-naphthylamine metabolism and toxicity in Chinese hamster ovary cell lines transfected with human CYP1A2 and NAT2*4, NAT2*5B or NAT2*7B N-acetyltransferase 2 haplotypes.
Habil MR; Salazar-González RA; Doll MA; Hein DW
Arch Toxicol; 2022 Nov; 96(11):2999-3012. PubMed ID: 36040704
[TBL] [Abstract][Full Text] [Related]
19. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
20. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
Ricart E; Taylor WR; Loftus EV; O'Kane D; Weinshilboum RM; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
Am J Gastroenterol; 2002 Jul; 97(7):1763-8. PubMed ID: 12135032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
